- ►ahajournals.org K Esposito, D Giugliano, F Nappo, R Marfella … - Circulation, 2004 - Am Heart Assoc Methods and Results— We performed a randomized, single-blind trial on 175
drug-naive patients with type 2 diabetes mellitus (93 men and 82 women), 35 to
70 years of age, selected from a population of 401 patients who ... Cited by 149 - Related articles - BL Direct - All 7 versions
- ►endojournals.org V Fonseca, C Desouza, S Asnani, I Jialal - Endocrine reviews, 2004 - Endocrine Soc People with type 2 diabetes are disproportionately affected by cardiovascular
disease (CVD), compared with those without diabetes. Traditional risk factors do
not fully explain this excess risk, and other "nontraditional" risk factors ... Cited by 84 - Related articles - BL Direct - All 6 versions
- ►glucagon.com [PDF] - Free from Publisher MC Riddle, DJ Drucker - Diabetes Care, 2006 - Am Diabetes Assoc Current therapies for type 2 diabetes are frequently associated with inadequate
control of postprandial hyperglycemia, weight gain, and, in the case of oral
agents, loss of efficacy over time. A better understanding of physiological ... Cited by 71 - Related articles - BL Direct - All 10 versions
- ►smh.com [PDF] J Albu, N Raja-Khan - Primary Care: Clinics in Office Practice, 2003 - Elsevier Obesity is a major worldwide epidemic that is associated with a significantly
increased risk of type 2 diabetes, cardiovascular disease, and premature death
[1 and 2]. Obesity is associated with increased mortality, especially when ... Cited by 38 - Related articles - BL Direct - All 4 versions
V Fonseca - Current Medical Research and Opinion®, 2003 - informahealthcare.com Measurement of glycosylated hemoglobin (HbA1C) remains the gold standard for the
assessment of glycemic control in patients with type 2 diabetes. Recent
investigations have studied the correlations between HbA1C levels and other ... Cited by 31 - Related articles - BL Direct - All 8 versions
MT Korytkowski - Pharmacotherapy, 2004 - PPI Sulfonylureas, which have evolved through two generations since their
introduction nearly 50 years ago, remain the most frequently prescribed oral
agents for treatment of patients with type 2 diabetes mellitus. Glyburide, ... Cited by 20 - Related articles - BL Direct - All 4 versions
- ►alfediam.org [PDF] G Paolisso, MR Rizzo, M Barbieri, D … - Diabetes and Metabolism, 2003 - Elsevier In type 2 diabetic patients mealtime glucose fluctuations are important
determinants of overall glucose control and overall risk of diabetes
cardiovascular complications. In fact, acute elevation of plasma glucose ... Cited by 12 - Related articles - BL Direct - All 4 versions
GI Uwaifo, RE Ratner - The American Journal of Cardiology, 2007 - Elsevier Cardiovascular disease (CVD) burden remains the predominant cause of mortality
and morbidity in the United States and in most of the developed world. The
ongoing twin epidemics of obesity and type 2 diabetes mellitus provide a ... Cited by 9 - Related articles - All 32 versions
EJ Abbink, PS van der Wal, CGJF Sweep, P … - Diabetes/Metabolism Reviews - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 4 - Related articles - BL Direct - All 5 versions
JL Gross, SRG Ferreira, JE de Oliveira - Arq Bras Endocrinol Metab, 2003 - SciELO Brasil A hiperglicemia pós-prandial (HPP) decorre da diminuição da primeira fase de
secreção insulínica e não tanto da resistência à insulina. Embora marcador
da glicemia pós-prandial (GPP), a glicemia de 2h (G2h) pós-sobrecarga ... Cited by 6 - Related articles - Cached - All 2 versions
